坏死性凋亡在肝炎以及其他肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2016.05.030

Abstract

Abstract: Traditionally cell death is divided into two categories,e.g. apoptosis and necrosis. But a growing body of research results show that the necrotic apoptosis is a kind of cell death different from necrosis and apoptosis,and plays an important role in a variety of diseases. Activation of necroptosis by ligands of death receptors requires the kinase activity of RIP1,which mediates the activation of RIP3 and MLKL,two critical downstream mediators of necroptosis. Blocking the kinase activity of RIP1,a key druggable target in the necroptosis pathway,by necrostatins inhibits the activation of necroptosis and allows cell survival and proliferation in the presence of death receptor ligands. In this review,we will discuss the difference between apoptosis,necrosis and necrotizing apoptosis,and we will summarizes the mechanism by which the necrotizing apoptosis occur in liver diseases.

Key words: Hepatitis, Necroptosis, Necrosis, Apoptosis

Song Jinyue, Ren Feng, Zhang Huanhu.. Necroptosis and its role in hepatitis and other liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 616-619.

References

[1] Ziegler U,Groscurth P. Morphological features of cell death. News Physiol Sci,2004,19（3）:124-128.
[2] Taylor RC,Cullen SP,Martin SJ. Apoptosis:controlled demolition at the cellular level. Nat Rev Mol Cell Biol,2008,9（3）:231-241.
[3] Proskuryakov SY,Konoplyannikov AG,Gabai VL. Necrosis:a specific form of programmed cell death. Exp Cell Res,2003,283（1）:1-16.
[4] Vanlangenakker N,VandenBerghe T,Krysko DV,et al. Molecular mechanisms and pathophysiologyof necrotic cell death. Curr Mol Med,2008,8（3）:207-220.
[5] Chan FK,Shisler J,Bixby JG,et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Chem Biol Phys Sci,2003,278（51）:51613-51621.
[6] Cho YS,Challa S,Moquin D,et al. Phosphorylation-driven assembly of the RIP1-RIP3complex regulates programmed necrosis and virus-inducedinflammation.Cell,2009,137（6）: 1112-1123.
[7] Fulda S. The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther,2013,14（11）: 999-1004.
[8] Wu W,Liu P,Li J. Necroptosis:an emerging form of programmed cell death. Crit Rev Oncol Hematol,2012,82（3）: 249-258.
[9] Holler N,Zaru R,Micheau O,et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol,2000,1（6）:489-495.
[10] Wu W,Liu P,Li J. Necroptosis:an emerging form of programmed cell death. Crit Rev Oncol Hematol,2012,82（3）: 249-258.
[11] Festjens N,Vanden Berghe T,Cornelis S,et al. RIP1,a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ,2007,14（3）:400-410.
[12] Degterev A,Huang Z,Boyce M,et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol,2005,1（2）:112-119.
[13] Moriwaki K,Chan FK. RIP3:a molecular switch for necrosis and inflammation. Genes Dev,2013,27（15）:1640-1649.
[14] An J,Mehrhof F,Harms C,et al. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J Hepatol,2013,58（2）:297-305.
[15] Roychowdhury S,McMullen MR,Pisano SG,et al. Absence of receptor interacting protein kinase 3 preventsethanol-induced liver injury. Hepatology,2013,57（5）:1773-1783.
[16] Ramachandran A,McGill MR,Xie Y,et al. Receptor interacting protein kinase 3 is a criticalearly mediator of acetaminophen-
induced hepatocyte necrosis in mice. Hepatology,2013,58（6）:2099-2108.
[17] Moriwaki K,Chan FK. RIP3:a molecular switch for necrosis and inflammation. Genes Dev,2013,27（15）:1640-1649.
[18] Zhang DW,Shao J,Lin J,et al. RIP3,an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science,2009,325（5938）:332-336.
[19] Mannon RB. Necroptosis in solid organ transplantation:a missing link to immune activation. Am J Transplant,2013,13（11）:2785-2786.
[20] Lau A,Wang S,Jiang J,et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant,2013,13（11）:2805-2818.
[21] Christofferson DE,Li Y,Hitomi J,et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis,2012,3（6）:e320-410.
[22] Berger SB,Kasparcova V,Hoffman S,et al. Cutting edge:RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol,2014,192（12）:5476-5480.
[23] Cuda CM,Misharin AV,Gierut AK,et al. Caspase-8 acts as a molecular rheostat to limit RIPK1-and MyD88-mediated dendritic cell activation. J Immunol,2014,192（12）:5548-5560.
[24] Vince JE,Wong WWL,Gentle I,et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.Immunity,2012,36（2）:215-227.
[25] Jouan-Lanhouet S,Arshad MI,Piquet-Pellorce C,et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ,2012,19（12）: 2003-2014.
[26] Liedtke C,Bangen JM,Freimuth J,et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology,2011,141（6）:2176-2187.
[27] Sharma M,Gadang V,Jaeschke A. Critical role for mixed lineage kinase 3 in acetaminophen-induced hepatotoxicity. Mol Pharmacol,2012,82（5）:1001-1007.
[28] Li JX,Feng JM,Wang Y,et al. The B-Raf（V600E） inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis,2014,5（6）:e1278.
[29] Roychowdhury S,Chiang DJ,Mandal P,et al. Inhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4 -induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res,2012,36（7）:1139-1147.
[30] Roychowdhury S,McMullen MR,Pisano SG,et al. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology,2013,57（5）:1773-1783.
[31] TakahashiN,Duprez L,Grootjans S,et al. Necrostatin-1 analogues:critical issues on the specificity,activity and in vivo use in experimental disease models. Cell Death Dis,2012,3（11）:e437.
[32] Vandenabeele P,Grootjans S,Callewaert N,et al. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ,2013,20（2）:185-187.
[33] Nagata K,Suzuki H,Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci,2007,32（5）:453-468.
[34] Csak T,Dolganiuc A,Kodys K,et al. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology,2011,53（6）: 1917-1931.
[35] Gautheron J,Vucur M,Reisinger F,et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med,2014,6（8）:1062-1074.
[36] Hotchkiss RS,Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med,2003,348（2）:138-150.
[37] Bantel H,Schulze-Osthoff K. Cell death in sepsis: a matter of how,when,and where. Crit Care,2009,13（4）:173.
[38] Duprez L,Takahashi N,Van Hauwermeiren F,et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity,2011,35（6）:908-918.
[39] Polykratis A,Hermance N,Zelic M,et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol,2014,193（4）:1539-1543.
[40] Newton K,Dugger DL,Wickliffe KE,et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science,2014,343（6177）:1357-1360.
[41] Linkermann A,Brasen JH,De Zen F, et al. Dichotomy between RIP1-and RIP3-mediated necroptosis in tumor necrosis factor-alpha-induced shock. Mol Med,2012,9（18）:577-586.
[42] Wu J,Huang Z,Ren J,et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res,2013,23（8）:994-1006.
[43] 陈柏年,杜冠华. 坏死性凋亡：一种新的细胞死亡方式.生理学进展,2010,41（02）：95-102.

Necroptosis and its role in hepatitis and other liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xu Fei, Li Weirong.. Protective effects of astragaloside in rats with CCL₄-induced liver injuries [J]. Journal of Practical Hepatology, 2019, 22(6): 808-811.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[9]	Wang Daowei, Fang Jian, Fan Ling.. Implication of serum IL-21 and chemokine levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2019, 22(6): 844-847.
[10]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[13]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[14]	Cai Meihong, Wang Qixia, Ma Xiong. Pathophysiology of hepatic ductopenia [J]. Journal of Practical Hepatology, 2019, 22(5): 620-623.
[15]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.